[{"id":"2c66d4b7-1c2e-4cd1-a61a-2f452cfb4042","acronym":"","url":"https://clinicaltrials.gov/study/NCT06470464","created_at":"2025-02-26T14:17:59.459Z","updated_at":"2025-02-26T14:17:59.459Z","phase":"Phase 2","brief_title":"Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor","source_id_and_acronym":"NCT06470464","lead_sponsor":"Shandong First Medical University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • epirubicin • thalidomide"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 06/16/2024","primary_completion_date":" 06/16/2024","study_txt":" Completion: 06/16/2024","study_completion_date":" 06/16/2024","last_update_posted":"2024-06-24"},{"id":"cb1eef0a-e163-46d8-8f49-52a6658d6c5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06256627","created_at":"2024-02-13T20:25:59.985Z","updated_at":"2024-07-02T16:35:19.538Z","phase":"","brief_title":"The Maintenance Treatment of \"ITIVA\" in AML Patients","source_id_and_acronym":"NCT06256627","lead_sponsor":"Henan Cancer Hospital","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • thalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-02-13"},{"id":"151a9d64-fe72-45af-9af7-b34da084781c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01661400","created_at":"2021-01-18T07:10:35.641Z","updated_at":"2024-07-02T16:35:21.403Z","phase":"Phase 1","brief_title":"Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors","source_id_and_acronym":"NCT01661400","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • thalidomide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 10/26/2012","start_date":" 10/26/2012","primary_txt":" Primary completion: 12/27/2023","primary_completion_date":" 12/27/2023","study_txt":" Completion: 12/27/2023","study_completion_date":" 12/27/2023","last_update_posted":"2024-01-31"},{"id":"c38bf8bf-b726-4684-ac2b-3f7adfe5aeb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01242267","created_at":"2021-01-18T05:00:11.712Z","updated_at":"2025-02-25T14:56:08.019Z","phase":"Phase 1/2","brief_title":"Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT","source_id_and_acronym":"NCT01242267","lead_sponsor":"Hackensack Meridian Health","biomarkers":" BCL2 • CD34","pipe":"","alterations":" ","tags":["BCL2 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • thalidomide • melphalan • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 05/11/2010","start_date":" 05/11/2010","primary_txt":" Primary completion: 01/20/2016","primary_completion_date":" 01/20/2016","study_txt":" Completion: 01/20/2016","study_completion_date":" 01/20/2016","last_update_posted":"2023-01-02"},{"id":"01402a98-429f-4cf2-b69d-75ccff5f707c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05198856","created_at":"2022-01-20T15:53:53.558Z","updated_at":"2024-07-02T16:36:18.276Z","phase":"Phase 1/2","brief_title":"Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC","source_id_and_acronym":"NCT05198856","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • thalidomide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 03/10/2024","primary_completion_date":" 03/10/2024","study_txt":" Completion: 12/10/2024","study_completion_date":" 12/10/2024","last_update_posted":"2022-01-20"},{"id":"490db03e-91ee-4e4c-afc6-b57bed9c3f1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00041080","created_at":"2021-01-18T00:02:59.271Z","updated_at":"2024-07-02T16:36:57.589Z","phase":"Phase 3","brief_title":"Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT00041080","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • thalidomide • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 139","initiation":"Initiation: 02/01/2003","start_date":" 02/01/2003","primary_txt":" Primary completion: 01/01/2011","primary_completion_date":" 01/01/2011","study_txt":" Completion: 01/01/2011","study_completion_date":" 01/01/2011","last_update_posted":"2019-07-30"},{"id":"4b3c5a90-7c09-4d7e-a807-bdb458ab8a9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03062800","created_at":"2021-01-18T15:05:07.285Z","updated_at":"2024-07-02T16:36:59.087Z","phase":"Phase 2","brief_title":"Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)","source_id_and_acronym":"NCT03062800","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" EGFR • VEGFA","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • thalidomide"],"overall_status":"Unknown status","enrollment":" Enrollment 232","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2019-06-05"},{"id":"39d94fa9-761b-4f7d-9a9b-52a865613e4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03777930","created_at":"2021-01-18T18:41:15.246Z","updated_at":"2024-07-02T16:37:04.517Z","phase":"Phase 4","brief_title":"The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol","source_id_and_acronym":"NCT03777930","lead_sponsor":"Shenzhen Fifth People's Hospital","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL21 • IL22","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL21 • IL22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e thalidomide • megestrol"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 12/10/2018","start_date":" 12/10/2018","primary_txt":" Primary completion: 10/10/2020","primary_completion_date":" 10/10/2020","study_txt":" Completion: 06/10/2021","study_completion_date":" 06/10/2021","last_update_posted":"2018-12-19"},{"id":"e30983bd-3ef7-4a75-984a-51ef448f0210","acronym":"CSWOG002","url":"https://clinicaltrials.gov/study/NCT03341494","created_at":"2021-01-18T16:30:15.849Z","updated_at":"2024-07-02T16:37:16.377Z","phase":"Phase 2","brief_title":"EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide","source_id_and_acronym":"NCT03341494 - CSWOG002","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • thalidomide"],"overall_status":"Unknown status","enrollment":" Enrollment 128","initiation":"Initiation: 04/01/2017","start_date":" 04/01/2017","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2017-11-14"},{"id":"1b940136-1411-4455-9d96-af20cf1be948","acronym":"","url":"https://clinicaltrials.gov/study/NCT00899080","created_at":"2021-01-18T03:27:19.009Z","updated_at":"2024-07-02T16:37:22.051Z","phase":"","brief_title":"Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide","source_id_and_acronym":"NCT00899080","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" CTSG","pipe":"","alterations":" ","tags":["CTSG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • thalidomide"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 07/04/2008","start_date":" 07/04/2008","primary_txt":" Primary completion: 08/04/2008","primary_completion_date":" 08/04/2008","study_txt":" Completion: 08/04/2008","study_completion_date":" 08/04/2008","last_update_posted":"2017-05-17"}]